These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34786649)

  • 1. Population Pharmacokinetic Analysis to Assist Dose Selection of the L-Ornithine Salt of Phenylacetic Acid.
    Wang X; Vilchez RA
    Clin Pharmacokinet; 2022 Apr; 61(4):515-526. PubMed ID: 34786649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exposures of Phenylacetic Acid and Phenylacetylglutamine Across Different Subpopulations and Correlation with Adverse Events.
    Wang X; Tseng J; Mak C; Poola N; Vilchez RA
    Clin Pharmacokinet; 2021 Dec; 60(12):1557-1567. PubMed ID: 34125423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics/pharmacodynamics of L-ornithine phenylacetate in overt hepatic encephalopathy and the effect of plasma ammonia concentration reduction on clinical outcomes.
    Safadi R; Rahimi RS; Thabut D; Bajaj JS; Ram Bhamidimarri K; Pyrsopoulos N; Potthoff A; Bukofzer S; Wang L; Jamil K; Devarakonda KR
    Clin Transl Sci; 2022 Jun; 15(6):1449-1459. PubMed ID: 35238476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.
    Zacharias HD; Zacharias AP; Gluud LL; Morgan MY
    Cochrane Database Syst Rev; 2019 Jun; 6(6):CD012334. PubMed ID: 31204790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L-ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure.
    Ytrebø LM; Kristiansen RG; Maehre H; Fuskevåg OM; Kalstad T; Revhaug A; Cobos MJ; Jalan R; Rose CF
    Hepatology; 2009 Jul; 50(1):165-74. PubMed ID: 19554542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy.
    Jalan R; Wright G; Davies NA; Hodges SJ
    Med Hypotheses; 2007; 69(5):1064-9. PubMed ID: 17467190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L-ornithine and phenylacetate synergistically produce sustained reduction in ammonia and brain water in cirrhotic rats.
    Davies NA; Wright G; Ytrebø LM; Stadlbauer V; Fuskevåg OM; Zwingmann C; Davies DC; Habtesion A; Hodges SJ; Jalan R
    Hepatology; 2009 Jul; 50(1):155-64. PubMed ID: 19437490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ornithine phenylacetate revisited.
    Jover-Cobos M; Noiret L; Sharifi Y; Jalan R
    Metab Brain Dis; 2013 Jun; 28(2):327-31. PubMed ID: 23456516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current state of knowledge of hepatic encephalopathy (part I): newer treatment strategies for hyperammonemia in liver failure.
    Kristiansen RG
    Metab Brain Dis; 2016 Dec; 31(6):1357-1358. PubMed ID: 27651377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders.
    Mokhtarani M; Diaz GA; Rhead W; Lichter-Konecki U; Bartley J; Feigenbaum A; Longo N; Berquist W; Berry SA; Gallagher R; Bartholomew D; Harding CO; Korson MS; McCandless SE; Smith W; Vockley J; Bart S; Kronn D; Zori R; Cederbaum S; Dorrani N; Merritt JL; Sreenath-Nagamani S; Summar M; Lemons C; Dickinson K; Coakley DF; Moors TL; Lee B; Scharschmidt BF
    Mol Genet Metab; 2012 Nov; 107(3):308-14. PubMed ID: 22958974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ornithine phenylacetate prevents disturbances of motor-evoked potentials induced by intestinal blood in rats with portacaval anastomosis.
    Oria M; Romero-Giménez J; Arranz JA; Riudor E; Raguer N; Córdoba J
    J Hepatol; 2012 Jan; 56(1):109-14. PubMed ID: 21835138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of ornithine phenylacetate in cirrhotic decompensated patients: an open-label, dose-escalating, single-cohort study.
    Ventura-Cots M; Arranz JA; Simón-Talero M; Torrens M; Blanco A; Riudor E; Fuentes I; Suñé P; Soriano G; Córdoba J
    J Clin Gastroenterol; 2013; 47(10):881-7. PubMed ID: 23751856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study.
    Stauch S; Kircheis G; Adler G; Beckh K; Ditschuneit H; Görtelmeyer R; Hendricks R; Heuser A; Karoff C; Malfertheiner P; Mayer D; Rösch W; Steffens J
    J Hepatol; 1998 May; 28(5):856-64. PubMed ID: 9625322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An orally deliverable ornithine-based self-assembling polymer nanomedicine ameliorates hyperammonemia in acetaminophen-induced acute liver injury.
    Ding Y; Koda Y; Shashni B; Takeda N; Zhang X; Tanaka N; Nishikawa Y; Nagasaki Y
    Acta Biomater; 2023 Sep; 168():515-528. PubMed ID: 37433359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ornithine phenylacetate targets alterations in the expression and activity of glutamine synthase and glutaminase to reduce ammonia levels in bile duct ligated rats.
    Jover-Cobos M; Noiret L; Lee K; Sharma V; Habtesion A; Romero-Gomez M; Davies N; Jalan R
    J Hepatol; 2014 Mar; 60(3):545-53. PubMed ID: 24512823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ammonia Removal by Metabolic Scavengers for the Prevention and Treatment of Hepatic Encephalopathy in Cirrhosis.
    Butterworth RF
    Drugs R D; 2021 Jun; 21(2):123-132. PubMed ID: 33890246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L-Ornithine phenylacetate reduces ammonia in pigs with acute liver failure through phenylacetylglycine formation: a novel ammonia-lowering pathway.
    Kristiansen RG; Rose CF; Fuskevåg OM; Mæhre H; Revhaug A; Jalan R; Ytrebø LM
    Am J Physiol Gastrointest Liver Physiol; 2014 Nov; 307(10):G1024-31. PubMed ID: 25258408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and Pharmacodynamic Properties of L-Ornithine L-Aspartate (LOLA) in Hepatic Encephalopathy.
    Kircheis G; Lüth S
    Drugs; 2019 Feb; 79(Suppl 1):23-29. PubMed ID: 30706424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic effect of L-ornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy].
    Chen MF; Li RC; Chen CH; Gao XC
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun; 25(6):718-9, 722. PubMed ID: 15958319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Mokhtarani M; Diaz GA; Rhead W; Berry SA; Lichter-Konecki U; Feigenbaum A; Schulze A; Longo N; Bartley J; Berquist W; Gallagher R; Smith W; McCandless SE; Harding C; Rockey DC; Vierling JM; Mantry P; Ghabril M; Brown RS; Dickinson K; Moors T; Norris C; Coakley D; Milikien DA; Nagamani SC; Lemons C; Lee B; Scharschmidt BF
    Mol Genet Metab; 2013 Dec; 110(4):446-53. PubMed ID: 24144944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.